These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 12808494)

  • 41. The role of the basal ganglia in the control of automatic visuospatial attention.
    Fielding J; Georgiou-Karistianis N; White O
    J Int Neuropsychol Soc; 2006 Sep; 12(5):657-67. PubMed ID: 16961947
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Basal ganglia, dopamine and temporal processing: performance on three timing tasks on and off medication in Parkinson's disease.
    Jones CR; Malone TJ; Dirnberger G; Edwards M; Jahanshahi M
    Brain Cogn; 2008 Oct; 68(1):30-41. PubMed ID: 18378374
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neural basis for impaired time reproduction in Parkinson's disease: an fMRI study.
    Elsinger CL; Rao SM; Zimbelman JL; Reynolds NC; Blindauer KA; Hoffmann RG
    J Int Neuropsychol Soc; 2003 Nov; 9(7):1088-98. PubMed ID: 14738289
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neuropsychological functioning following bilateral subthalamic nucleus stimulation in Parkinson's disease.
    Morrison CE; Borod JC; Perrine K; Beric A; Brin MF; Rezai A; Kelly P; Sterio D; Germano I; Weisz D; Olanow CW
    Arch Clin Neuropsychol; 2004 Mar; 19(2):165-81. PubMed ID: 15010083
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The impact of executive functions on verb production in patients with Parkinson's disease.
    Colman KS; Koerts J; van Beilen M; Leenders KL; Post WJ; Bastiaanse R
    Cortex; 2009 Sep; 45(8):930-42. PubMed ID: 19303593
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Absence of cognitive deficits following deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease.
    Fraraccio M; Ptito A; Sadikot A; Panisset M; Dagher A
    Arch Clin Neuropsychol; 2008 Jul; 23(4):399-408. PubMed ID: 18394859
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Visuoperceptual processing in Parkinson's disease: from the retina to the frontal cortex].
    Ruiz-Sánchez de León JM; Fernández-Guinea S
    Rev Neurol; 2005 May 1-15; 40(9):557-62. PubMed ID: 15898018
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Levodopa and cognitive disorders in Parkinson's disease].
    Leiva-Santana C; Alvarez-Saúco M
    Rev Neurol; 2006 Jul 16-31; 43(2):95-100. PubMed ID: 16838257
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Sleep disturbances and their effect on the sustained attention in patients with Parkinson's disease].
    Kułakowska A; Kapica-Topczewska K; Halicka D; Drozdowski W
    Pol Merkur Lekarski; 2008 Feb; 24(140):109-12. PubMed ID: 18634265
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Visual selective attention in Parkinson's disease: dissociation of exogenous and endogenous inhibition.
    Grande LJ; Crosson B; Heilman KM; Bauer RM; Kilduff P; McGlinchey RE
    Neuropsychology; 2006 May; 20(3):370-82. PubMed ID: 16719630
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Selective attention deficits in early and moderate stage Parkinson's disease.
    Zhou S; Chen X; Wang C; Yin C; Hu P; Wang K
    Neurosci Lett; 2012 Feb; 509(1):50-5. PubMed ID: 22230890
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cognitive profile of patients with newly diagnosed Parkinson disease.
    Muslimovic D; Post B; Speelman JD; Schmand B
    Neurology; 2005 Oct; 65(8):1239-45. PubMed ID: 16247051
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The concept of bradyphrenia.
    Lees AJ
    Rev Neurol (Paris); 1994 Dec; 150(12):823-6. PubMed ID: 7676117
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Attention disorders in Parkinson disease patients].
    Danilova DP
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1980; 80(5):694-6. PubMed ID: 7415692
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Basal ganglia and beyond: The interplay between motor and cognitive aspects in Parkinson's disease rehabilitation.
    Ferrazzoli D; Ortelli P; Madeo G; Giladi N; Petzinger GM; Frazzitta G
    Neurosci Biobehav Rev; 2018 Jul; 90():294-308. PubMed ID: 29733882
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Frontal dysfunction in early Parkinson's disease.
    Farina E; Cappa SF; Polimeni M; Magni E; Canesi M; Zecchinelli A; Scarlato G; Mariani C
    Acta Neurol Scand; 1994 Jul; 90(1):34-8. PubMed ID: 7941954
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cognitive deficits in Parkinson's disease.
    Dubois B; Pillon B
    J Neurol; 1997 Jan; 244(1):2-8. PubMed ID: 9007738
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Time perception in patients with depressed consciousness and Parkinson's disease. I. Experimental results.
    Austin G; Hayward W
    Confin Neurol; 1969; 31(1):22-36. PubMed ID: 4900485
    [No Abstract]   [Full Text] [Related]  

  • 59. Disorders of the anterior attentional-intentional system in patients with end stage renal disease: Evidence from reaction time studies.
    Harciarek M; Michałowski J; Biedunkiewicz B; Williamson J; Dębska-Ślizień A; Rutkowski B; Heilman KM
    Brain Cogn; 2016 Aug; 107():1-9. PubMed ID: 27363003
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The ability to consent to Parkinson disease research.
    Klein E
    Neurology; 2013 Aug; 81(9):e62-4. PubMed ID: 23978729
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.